Among the hundreds of predictive models developed for cardiovascular disease, less than one-tenth of 1% actually end up routinely used in clinical practice. CV-Ai2 uses data from clinical practice and analytic intelligence to solve clinical problems and create solutions that can be applied in real-world patient care.

The research program aims to advance cardiovascular biology and medicine by focusing on pluripotent stem cell-based modeling and therapy and by nurturing future leaders in regenerative medicine.

Hypertension in children is a major cause of disease, including early onset heart disease. Up to 25% of children who are overweight or obese have hypertension (high blood pressure), and children with obesity are at greater risk for having other cardiovascular disease risk factors such as high cholesterol and diabetes. The ReNEW Clinic at The Johns Hopkins University provides an innovative multidisciplinary approach to the evaluation and treatment of obesity-related hypertension to help prevent and treat cardiovascular disease. This clinic is designed for children with elevated blood pressure (prehypertension and hypertension) and a BMI at or above the 85th percentile. Many children in this clinic are enrolled in a longitudinal registry to help researchers learn how to better care for children with multiple risk factors for heart disease.

Read more about the ReNEW clinic: Childhood Obesity: A Focus on Hypertension

The Paul Ladenson Lab studies the application of thyroid hormone analogues for treating cardiovascular disease; novel approaches to thyroid cancer diagnosis and management; and the health economic analyses related to thyroid patient care.

The Pluznick Lab is interested in the role that chemosensation plays in regulating physiological processes, particularly in the kidney and the cardiovascular system. We have found that sensory receptors (olfactory receptors, taste receptors, and other G-protein coupled receptors) are expressed in the kidney and in blood vessels, and that individual receptors play functional roles in whole-animal physiology. We are currently working to identify the full complement of sensory receptors found in the kidney, and are working to understand the role that each receptor plays in whole-animal physiology by using a variety of in vitro (receptor localization, ligand screening) and in vivo (whole-animal physiology) techniques.

The Post Lab is involved in the Multi-Ethnic Study of Atherosclerosis (MESA), a collaborative study of the characteristics of subclinical cardiovascular disease (that is, disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. As MESA researchers, we study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States, including Johns Hopkins University. Each participant received an extensive physical exam to determine a number of conditions, including coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits have allowed study of the progression of disease. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. Wendy S. Post, MD, MS, is an associate faculty, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, and a professor of medicine.

Our research is centered on the safety, efficacy and outcomes of PCI performed at hospitals without on-site cardiac surgery. Active projects: C-PORT Randomized Studies and Registries; New Jersey Angioplasty Demonstration Project; InCar-decision support tools for performance of PCI at hospitals without on-site cardiac surgery. For more information please visit Cport.org.

Research in the Josef Coresh Lab focuses on cardiovascular epidemiology, kidney disease and genetic epidemiology. Our team uses innovative methods to quantify disease burden and consequences in the population; studies the causes and consequences of vascular disease in the heart, kidneys and brain; and works to develop a strong scientific basis for quantifying the burden, causes and consequences of kidney disease. Working in collaboration with leading laboratories and specialists, we also aim to quantify the interplay of genes and environment in health and disease.

Research in the Jochen Steppan Lab primarily focused on vascular stiffness related to aging. We are currently researching LOXL2 (lysine-oxidase-like-2), which might be intimately involved in the development or progression of vascular stiffness. We aim to better understand LOXL2's role in the vasculature and hope that this work leads to the characterization of a novel therapeutic target. This is important in the treatment of cardiovascular diseases in the aging population.

Research in the J. Hunter Young Lab focuses on the genetic epidemiology and physiology of cardiovascular disease and its risk factors, especially hypertension, diabetes and obesity. Current activities include an observational study of hypertension among African Americans; a genetic epidemiology study of worldwide cardiovascular disease susceptibility patterns; and several population-based observational studies of cardiovascular and renal disease. A recent focus group study found that changes in housing and city policies might lead to improved environmental health conditions for public housing residents.